Final results of a large, community-based, prospective study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy

Journal of Supportive Oncology

Volumn 5, Issue 4 SUPPL. 2, 2007, Pages 38-39

  Ozer, H ^a   Mirtsching, B ^a   Rader, M ^a   Ding, B ^a   Truscinski, D ^a   Dreiling, L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMMUNITY; COMORBIDITY; CONFERENCE PAPER; DEATH; DEHYDRATION; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PROSPECTIVE STUDY; SEPTIC SHOCK;

EID: 34250634013     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Ozer H, Mirtsching B, Rader M, Ding B,Truscinski D, Dreiling L. Final results of a large, community-based, prospective study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2-6,2006; Atlanta, Georgia. Abstract 8569.